Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation - Biology of Blood and Marrow Transplantation
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma | Bone Marrow Transplantation
Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial | Bone Marrow Transplantation
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma - Biology of Blood and Marrow Transplantation
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic
High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review | Bone Marrow Transplantation
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma | Bone Marrow Transplantation
813-Autologous conditioning high dose melphalan 140 mg/m<sup>2</sup> | eviQ
A novel pro-oxidant combination of resveratrol and copper reduces transplant related toxicities in patients receiving high dose melphalan for multiple myeloma (RESCU 001) | PLOS ONE
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma - Clinical Lymphoma, Myeloma and Leukemia
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | NEJM
Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma | Bone Marrow Transplantation
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis | NEJM
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan - The Lancet Haematology
High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease - Kidney International
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis | Bone Marrow Transplantation
Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma | Bone Marrow Transplantation
Frontiers | Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy
Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis - Transplantation and Cellular Therapy, Official Publication of the American Society ...
Role of high-dose Melphalan & ASCT | Int'l Myeloma Fn
Studies Comparing High-Dose Melphalan and Autologous SCT with... | Download Table
A Phase 1/2 Trial of Carfilzomib + High Dose Melphalan Conditioning for Auto-HCT Followed by Carfilzomib Maintenance for Patients with Relapsed Multiple Myeloma - Biology of Blood and Marrow Transplantation
